NCT00691873View on ClinicalTrials.gov

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

October 31, 2007

Conditions
Asthma
Interventions
DRUG

Placebo

placebo

DRUG

Xolair

Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.

Trial Locations (1)

39216

University of Mississippi Medical Center, Jackson

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Mississippi Medical Center

OTHER